{"nctId":"NCT00929695","briefTitle":"Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease","startDateStruct":{"date":"2009-06"},"conditions":["Graft Versus Host Disease","Recurrent Adult Acute Lymphoblastic Leukemia"],"count":164,"armGroups":[{"label":"Arm I (Low-dose)","type":"EXPERIMENTAL","interventionNames":["Drug: prednisone","Drug: methylprednisolone","Other: questionnaire administration"]},{"label":"Arm II (Standard-dose)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: prednisone","Drug: methylprednisolone","Other: questionnaire administration"]}],"interventions":[{"name":"prednisone","otherNames":["DeCortin","Deltra"]},{"name":"methylprednisolone","otherNames":["Depo-Medrol","Medrol","MePRDL","Solu-Medrol","Wyacort"]},{"name":"questionnaire administration","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with newly diagnosed acute GVHD (\\>= grade IIa) for whom, in the judgment of the attending physician, initial treatment with systemic glucocorticoids is indicated\n* Patient or guardian able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Hallmarks of chronic GVHD\n* GVHD after donor lymphocyte infusion (DLI)\n* Patient unwilling to remain in Seattle under the care of the Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA) through day 42 after the start of treatment for GVHD\n* Uncontrolled infection or other underlying comorbidity (i.e. severe psychiatric illness) that precludes the use of \"standard-dose\" prednisone\n* Recent diagnosis of recurrent or progressive malignancy that precludes the use of \"standard-dose\" prednisone\n* Any prior systemic therapy for acute GVHD (Patients may receive up to 2 doses of low-dose prednisone prior to randomization; low-dose prednisone is defined as 0.5 mg/kg/dose for patients who present with grade IIa GVHD and 1 mg/kg/dose for those who present with grade IIb-IV GVHD)\n* Enrollment on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) trial 0802","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment","description":"The total cumulative dose of prednisone (milligrams/kilogram) was calculated starting from the start of therapy through study day 42.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":"13.7"},{"groupId":"OG001","value":"27.1","spread":"12.7"},{"groupId":"OG002","value":"38.4","spread":"14.1"},{"groupId":"OG003","value":"41.3","spread":"12.1"}]}]}]},{"type":"SECONDARY","title":"Prednisone-associated Toxicity as Assessed by Hyperglycemia","description":"Impact on blood glucose (BG) control will be assessed by comparing average BG and BG-variability between patients given standard-dose and low-dose prednisone.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":"7.4"},{"groupId":"OG001","value":"142","spread":"12.9"}]}]}]},{"type":"SECONDARY","title":"Prednisone-associated Toxicity as Assessed by Invasive Infections (Bacterial, Fungal and Viral)","description":"The total number of invasive infections (bacterial, fungal and viral) occurring in patients in each group were collected.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Prednisone-associated Toxicity as Assessed by Myopathy","description":"Assessed by mean change from baseline to day 42 using Manual Muscle Testing measure. The degree of resistance against pressure applied by tester was measured on a 5-point scale. A score of 5 indicates the patient can hold the position against maximum to strong resistance. A score of 0 indicates the patient has no resistance against pressure. Testing included upper and lower extremities: shoulder (deltoid at 90 degrees), and hip and knee in a sitting position.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":null},{"groupId":"OG001","value":"-0.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Prednisone-associated Toxicity as Assessed by Hypertension","description":"The number of different anti-hypertensive medications administered to control hypertension were collected. The mean change in the number of medications from baseline to day 42 was measured.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":null},{"groupId":"OG001","value":"-0.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Prednisone-associated Toxicity as Assessed by Quality of Life","description":"Patients completed the MD Anderson Symptom Inventory (MDASI), which is a quality of life questionnaire validated for oncology/transplant patients. On a 1-10 point scale, patients scored the degree of severity of symptoms or the degree of interference in feelings or function due to symptoms at baseline or in the previous week. A score of 1 indicates symptom is not present or does not interfere with feelings or function. A score of 10 indicates the symptom is as bad as you can imagine or interferes completely with feelings or function. The mean change in score from baseline to day 42 was measured.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-relapse Mortality","description":"Non-relapse mortality (NRM) is defined as death due to any cause in the absence of documented relapse/progression.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrent or Progressive Malignancy","description":"Percentage of relapse estimated by cumulative incidence methods","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression to Grade III-IV Acute GVHD","description":"Diagnosed and graded according to standard established criteria. Measure is percent of patients with baseline scores of IIa (Group A) or IIb (Group B) who progressed to more severe GVHD (Grade III/IV). Percentage estimated by cumulative incidence methods.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Therapy for Acute GVHD Beyond Prednisone","description":"This includes any intervention intended to control acute GVHD through an immunosuppressive effect from oral or parenteral administration of any systemic medication not given previously. This does not include topical therapy, an increase in the dose of glucocorticoids or the resumption of treatment after previous discontinuation or any increase in the dose of immunosuppressive medication previously administered for GVHD prophylaxis, or reinstatement of GVHD prophylaxis previously discontinued. A change in treatment from cyclosporine to tacrolimus or vice versa because of drug toxicity is not considered secondary therapy, but any change made because of uncontrolled GVHD is considered secondary therapy. Percentage is estimated by cumulative incidence methods.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Chronic Extensive GVHD","description":"Percentage of patients with chronic extensive GVHD, estimated by cumulative incidence methods","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Percentage of patients surviving as estimated by Kaplan-Meier.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":38,"n":81},"commonTop":[]}}}